PARTNERSHIP WITH PFIZER WILL ENHANCE BIOMEDICAL RESEARCH

PFIZER CHILE’S CENTER OF EXCELLENCE IN PRECISION MEDICINE (CEMP) AND OUR UNIVERSITY WILL JOIN EXPERIENCES TO INCREASE THE VALUE OF APPLIED TECHNOLOGIES.



June 08, 2017

A strong focus on the research field, to explore and develop joint work initiatives in the field of biomedical research is included in the collaboration agreement signed between our University and the Center for Excellence in Precision Medicine (Cemp), belonging to the biomedical and pharmaceutical company Pfizer Chile.
 
 
The agreement was formalized on June 7, at the Headquarters, with the signing of President Alvaro Rojas and the Executive Director of Cemp, Ricardo Avila.
 
 
Alvaro Rojas highlighted the efforts to be undertaken by the University to realize this Convention via concrete actions and effective therapies. "Precision Medicine is the new way of doing medicine and pharmacology. Each patient has certain peculiarities and the right treatment must be given that corresponds to his or her genetic and phenotypic condition," he said.
 
 
At the same time, he emphasized the alliance signed with the Center for Excellence sponsored by Corfo. "For our institution it is very important to complement the capabilities and increase the value of the research conducted. In this sense, we will make it available to this initiative our best scientists and professionals from different disciplines in the field of science in order to address major challenges in the population, such as lung cancer or gastric cancer," he said.
 
 
For the executive director of The Cemp this new collaboration network constitutes a contribution to the development of the biotechnological research ecosystem in Chile. "The University of Talca has a competitive advantage in the field of Precision Medicine, since it has a very strong human capital that will allow us to seek synergy to explore opportunities for joint research," he said.
 
 
Ricardo Avila added that one of the strengths of our Academic Institution is frontier research. "The concept of precision medicine seeks more sensitive and less invasive methods for diagnosis and this is achieved with bioinformatics and technological capabilities. In this sense, you are not alien to it, since you have a Center for Bioinformatics and Molecular Simulation that allows you to process the molecular analysis and impact all areas of knowledge," he said.
 
 
For its part, the Dean of the Department of Health Sciences, Carlos Padilla, highlighted this partnership between UTALCA researchers and Pfizer Chile. "We are very pleased with this agreement, because the biomedical sciences are one of the most dynamic disciplines at the global level, but also the most expensive. With this partnership we will be able to raise new projects partners and we also hope to align the developments of the research generated through the Doctorate and Master's Degree in Biomedical Sciences, as it includes precision medicine and cancer study at different levels," he concluded.
 
 
From another perspective, Corfo’s Technological Centers Coordinator, Gerardo Gallardo, highlighted the agreement as a major step forward to push the development of biomedical research. "The future sustainability of this Center supported by the Technological Capabilities Management is a tremendous benefit for the Country, since it is positioned as a pole of regional development in biotechnological innovation," he said.



ACADEMICS DEVELOP A VIDEO GAME THAT TEACHES AND ENTERTAINS


PARTNERSHIP WITH PFIZER WILL ENHANCE BIOMEDICAL RESEARCH
CTA GOT X-RAY GUN FOR CONTAMINATION DETECTION
ARCHIVE